Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg nudges up target price on Admiral ahead of FY results

(Sharecast News) - Analysts at Berenberg nudged up their target price on insurer Admiral Group from 3,292.0p to 3,300.0p on Wednesday ahead of the company's FY24 results next week. Berenberg pointed out that since its January 2025 outlook note, Admiral shares were up more than 10% and, heading into the FY24 results, it remains positive on both the company and the sector.

"Our FY24 and FY25 EPS estimates are 5% and 4% above consensus estimates respectively (we note our above-consensus estimate in FY24 is partly driven by a better IFRS 17 quota share result, which we do not expect to repeat in FY25)," said Berenberg.

The German bank also noted that it expects investors will be "keenly listening" for updates on pricing developments in Q125 and Admiral's perspective on the latest Financial Conduct Authority regulatory developments.

"We maintain our view that the market is overly negative on pricing and regulatory risks and, with the stock trading at a 20% discount to its five-year average, we continue to find the valuation attractive," said Berenberg, which reiterated its 'buy' rating on the stock.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.